See if spironolactone can reduce aortic stiffness in adults with thoracic aortic aneurysm
Official title: Hemodynamic Effects Of Aldosterone Receptor Blockade In Degenerative Thoracic Aortic Aneurysm: A Pilot Randomized Controlled Trial (HEART: Pilot RCT)
Run by Mayo Clinic · NCT07483177 · Data updated 2026-11-12
This study tests whether spironolactone reduces aortic stiffness compared with placebo in adults with degenerative thoracic aortic aneurysms.
Quick facts
| Phase | Phase1; Phase2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | Mayo Clinic Academic / other |
| Locations | 1 site (Rochester, Minnesota) |
| Status | Recruiting |
| Started | May 25, 2026 |
| Main results expected | May 2028 |
| Study ends | May 2028 |
| Registry record updated | June 8, 2026 |
| Trial ID | NCT07483177 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18 years and older with degenerative thoracic aortic aneurysm meeting size thresholds and stable kidney function, who are not on conflicting medications and do not have excluded conditions.
✕Probably not a fit
Patients with heritable aortopathies, prior aortic surgery, certain arrhythmias, or contraindications to spironolactone may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This pilot randomized controlled trial compares spironolactone to placebo in adults with degenerative thoracic aortic aneurysm to see if the medication lowers aortic stiffness, measured by carotid-femoral pulse wave velocity. The trial includes adults 18 and older with aneurysm thresholds adjusted for age, sex, and body size, and requires stable or no antihypertensive therapy. Key safety criteria include adequate kidney function and potassium levels, with exclusions for certain heritable aortopathies, prior aortic surgery, and other conditions that could affect measurement. The study is conducted at Mayo Clinic in Rochester, and is led by Mayo Clinic with no listed collaborators.
Why it matters
Potential benefit: If successful, spironolactone could reduce aortic stiffness and potentially slow progression of thoracic aortic aneurysm.
How similar studies have gone: Previous research in related areas has explored mineralocorticoid receptor antagonists for vascular stiffness, but this exact approach in degenerative thoracic aortic aneurysm is novel and exploratory.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria 1. Adults ≥ 18 years old with dTAA of the aortic root and/or ascending aorta exceeding the upper limit of normal for age, sex, and body surface area (≥ 4.0 cm as an example of a common threshold; but age, sex and body size-specific thresholds have been established for the aortic root24 and ascending aorta25); 2. no antihypertensive use or stable antihypertensive regimen ≥ 4 weeks; 3. eGFR ≥ 50 mL/min/1.73 m²; 4. serum potassium ≤ 5.1 mmol/L; 5. ability to provide informed consent. Exclusion Criteria 1. Heritable aortopathies (Marfan, Loeys-Dietz, vascular Ehlers-Danlos, Turner syndromes; familial TAA, genetically-proven TAA); 2. bicuspid aortic valve; 3. inflammatory aortitis, 4. prior aortic surgery, endovascular repair, or acute aortic syndrome; 5. permanent atrial fibrillation/flutter; 6. major peripheral artery disease affecting the carotids, iliacs and/or external femoral arteries precluding cfPWV measurement; 7. current use of spironolactone, eplerenone or finererone; 8. pregnancy or lactation.
Where it's running
-
Mayo Clinic in Rochester
Rochester, Minnesota, United States Recruiting
Study contacts
- Principal investigator: Thais Coutinho — Mayo Clinic
- Study coordinator: Saad Omar
- Email: omar.saad@mayo.edu
- Phone: 507-538-5162
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
GORE MBA Arch Endoprosthesis Early Feasibility Study
This study tests the safety of the MBA device in people with arch-related thoracic aortic diseases to see if it can be used safely in real-world settings.
-
Evaluating outcomes of thoracic aortic repair in patients with compromised landing zones
This study is testing different stent-graft options for patients with aortic aneurysms who have tricky anatomy to see if they can prevent complications after surgery.
-
Advancing genomic medicine using electronic health records
This study is trying to see if using electronic health records and helpful reminders can get more patients tested for genetic conditions in a way that doctors can easily use.
-
Exploring genetic factors in acute aortic conditions
This study is testing whether looking at the genes of people with aortic dissection or aneurysm can help doctors better predict who is at risk and improve their chances of getting timely treatment.
-
Using presepsin levels to guide antibiotic treatment in thoracic aorta surgery patients
This study is testing if measuring a specific marker in the blood can help doctors give the right antibiotics to patients after thoracic aorta surgery to prevent infections and improve recovery.
-
Evaluating outcomes of custom-made aortic devices
This study looks at how well custom-made aortic devices work for people with thoracic aortic disease after they've had a specific repair procedure.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.